Literature DB >> 34245817

Pathogenic Variants in the Genes Affected in Alport Syndrome (COL4A3-COL4A5) and Their Association With Other Kidney Conditions: A Review.

Judy Savige1, Philip Harraka2.   

Abstract

Massively parallel sequencing identifies pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) in as many as 30% of individuals with focal and segmental glomerulosclerosis (FSGS), 10% of those with kidney failure of unknown cause, and 20% with familial immunoglobulin A (IgA) glomerulonephritis. FSGS associated with COL4A3-COL4A5 variants is usually present by the onset of kidney failure and may develop because the abnormal glomerular membranes result in podocyte loss and secondary hyperfiltration. The association of COL4A3-COL4A5 variants with kidney failure or IgA glomerulonephritis may be coincidental. However, pathogenic variants in these conditions occur more often than they should by chance, which suggests that the variants are disease-causing. COL4A3-COL4A5 variants are also found in cystic kidney diseases after autosomal dominant polycystic kidney disease has been excluded. COL4A3-COL4A5 variants should be suspected in individuals with FSGS, kidney failure of unknown cause, or familial IgA glomerulonephritis, especially where there is persistent hematuria and a family history of hematuria or kidney failure.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Alport syndrome (AS); COL4A3; COL4A4; COL4A5; GBM thinning; IgA glomerulonephritis; collagen IV; cystic kidney disease; focal and segmental glomerulosclerosis (FSGS); genetic kidney disease; glomerular basement membrane (GBM); renal failure; review

Mesh:

Substances:

Year:  2021        PMID: 34245817     DOI: 10.1053/j.ajkd.2021.04.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Pathogenic LAMA5 Variants and Kidney Disease.

Authors:  Judy Savige; Philip Harraka
Journal:  Kidney360       Date:  2021-12-30

Review 2.  Molecular and Cellular Mechanisms Underlying the Initiation and Progression of Alport Glomerular Pathology.

Authors:  Dominic Cosgrove; Jacob Madison
Journal:  Front Med (Lausanne)       Date:  2022-02-09

3.  The 2019 and 2021 International Workshops on Alport Syndrome.

Authors:  Sergio Daga; Jie Ding; Constantinos Deltas; Judy Savige; Beata S Lipska-Ziętkiewicz; Julia Hoefele; Frances Flinter; Daniel P Gale; Marina Aksenova; Hirofumi Kai; Laura Perin; Moumita Barua; Roser Torra; Jeff H Miner; Laura Massella; Danica Galešić Ljubanović; Rachel Lennon; Andrè B Weinstock; Bertrand Knebelmann; Agne Cerkauskaite; Susie Gear; Oliver Gross; A Neil Turner; Margherita Baldassarri; Anna Maria Pinto; Alessandra Renieri
Journal:  Eur J Hum Genet       Date:  2022-03-09       Impact factor: 5.351

Review 4.  Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome.

Authors:  Judy Savige; Mary Huang; Marina Shenelli Croos Dabrera; Krushnam Shukla; Joel Gibson
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 5.  Heterozygous Pathogenic COL4A3 and COL4A4 Variants (Autosomal Dominant Alport Syndrome) Are Common, and Not Typically Associated With End-Stage Kidney Failure, Hearing Loss, or Ocular Abnormalities.

Authors:  Judy Savige
Journal:  Kidney Int Rep       Date:  2022-06-07

6.  Novel heterozygous mutation in COL4A4 responsible for Alport syndrome in a Chinese family.

Authors:  Ran Du; Jishi Liu; Yiqiao Hu; Song Peng; Liangliang Fan; Rong Xiang; Hao Huang
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.